How I manage infection risk and prevention in patients with lymphoid cancer

Infections are a common cause of morbidity and mortality in patients with lymphoid cancer. Because cancer therapeutics, including new targeted therapies and immunotherapies, are evolving, clinicians need to be aware of additional risk factors and infections that may arise in patients treated with these agents. This article highlights fundamental issues in treating patients with lymphoid cancer, including risk factors for infection, screening for infectious diseases, and recommendations for antimicrobial prophylaxis in patients with lymphoid cancers. We present 4 scenarios of patients with lymphoid cancers who have various infections, and we describe a treatment approach based on a combination of evidence-based data and experience because objective data are limited regarding infections, especially with newer agents. The goal of this discussion is to provide a framework for institutions and health care providers to help them develop their own approach to preventing and treating infections in patients with lymphoid cancer.

Automated summary

This article highlights the fundamental issues in treating infections in lymphoid cancer patients, including risk factors, screening, and antimicrobial prophylaxis recommendations. It provides a treatment approach based on evidence-based data and experience. The goal is to assist institutions and healthcare providers in developing their own strategies for preventing and treating infections in lymphoid cancer patients.